PCR ribotype prevalence and molecular basis of macrolide-lincosamide-streptogramin B (MLSB) and fluoroquinolone resistance in Irish clinical Clostridium difficile isolates

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 9, 2011, Pages 1976-1982

  Solomon, Katie ^a   Fanning, Seamus ^a   McDermott, Sinead ^b   Murray, Sean ^a   Scott, Louise ^b   Martin, Alan ^a,c   Skally, Mairead ^d   Burns, Karen ^e   Kuijper, Ed ^f   Fitzpatrick, Fidelma ^d,e   Fenelon, Lynda ^b   Kyne, Lorraine ^a,c  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^d HEALTH PROTECTION SURVEILLANCE CENTRE   (Ireland)

^e BEAUMONT HOSPITAL   (Ireland)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibiotic associated diarrhoea; Antimicrobial resistance surveillance; DNA gyrase; Erm; Healthcare associated infections

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; DNA TOPOISOMERASE (ATP HYDROLYSING); ERYTHROMYCIN; LEVOFLOXACIN; LINCOSAMIDE; MACROLIDE; MIKAMYCIN B; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DNA POLYMORPHISM; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; POLYMERASE CHAIN REACTION; PREVALENCE; RIBOTYPING;

AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CLOSTRIDIUM DIFFICILE; DNA GYRASE; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FLUOROQUINOLONES; HUMANS; IRELAND; LINCOSAMIDES; MACROLIDES; METHYLTRANSFERASES; MICROBIAL SENSITIVITY TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOTYPING; STREPTOGRAMIN B;

EID: 80051674257     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr275     Document Type: Article

References (39)

1. Drudy D, Goorhuis B, Bakker D et al. Clindamycin-resistant clone of Clostridium difficile PCR ribotype 027, Europe. Emerg Infect Dis 2008; 14: 1485-7.
2. Fenner L, Widmer AF, Stranden A et al. First cluster of clindamycinresistant Clostridium difficile PCR ribotype 027 in Switzerland. Clin Microbiol Infect 2008; 14: 514-5.
3. Johnson S, Samore MH, Farrow KA et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999; 341: 1645-51.
4. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995; 39: 577-85.
5. Arthur M, Brisson-Noel A, Courvalin P. Origin and evolution of genes specifying resistance to macrolide, lincosamide and streptogramin antibiotics: data and hypotheses. J Antimicrob Chemother 1987; 20: 783-802.
6. Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991; 35: 1267-72.
7. B) resistance determinant in strains of Clostridium difficile. Microb Drug Resist 2002; 8: 45-53.
8. Bendle JS, James PA, Bennett PM et al. Resistance determinants in strains of Clostridium difficile from two geographically distinct populations. Int J Antimicrob Agents 2004; 24: 619-21.
9. Roberts MC, McFarland LV, Mullany P et al. Characterization of the genetic basis of antibiotic resistance in Clostridium difficile. J Antimicrob Chemother 1994; 33: 419-29.
10. Roberts MC, Sutcliffe J, Courvalin P et al. Nomenclature for macrolide and macrolide-lincosamide-streptogramin B antibiotic resistance determinants. Antimicrob Agents Chemother 1999; 43: 2823-30.
11. Farrow KA, Lyras D, Rood JI. The macrolide-lincosamidestreptogramin B resistance determinant from Clostridium difficile 630 contains two erm(B) genes. Antimicrob Agents Chemother 2000; 44: 411-3.
12. Farrow KA, Lyras D, Rood JI. Genomic analysis of the erythromycin resistance element Tn5398 from Clostridium difficile. Microbiology 2001; 147: 2717-28.
13. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996; 40: 1817-24.
14. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002; 34: 482-92.
15. Hooper DC. Mechanisms of fluoroquinolone resistance. Drug Resist Updat 1999; 2: 38-55.
16. Spigaglia P, Barbanti F, Louie T et al. Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinoloneresistant Clostridium difficile mutants selected in vitro. Antimicrob Agents Chemother 2009; 53: 2463-8.
17. Drudy D, Quinn T, O'Mahony R et al. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother 2006; 58: 1264-7.
18. Spigaglia P, Barbanti F, Mastrantonio P et al. Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 2008; 57: 784-9.
19. Walkty A, Boyd DA, Gravel D et al. Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates. Diagn Microbiol Infect Dis 2010; 66: 419-24.
20. Zaiss NH, Witte W, Nubel U. Fluoroquinolone resistance and Clostridium difficile, Germany. Emerg Infect Dis 2010; 16: 675-7.
21. Huang H, Weintraub A, Fang H et al. Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains. Anaerobe 2010; 16: 633-5.
22. B) resistance with resistance to moxifloxacin in Clostridium difficile. J Antimicrob Chemother 2003; 51: 599-603.
23. Ackermann G, Tang YJ, Kueper R et al. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob Agents Chemother 2001; 45: 2348-53.
24. Dridi L, Tankovic J, Burghoffer B et al. gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother 2002; 46: 3418-21.
25. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006; 12 Suppl 6: 2-18.
26. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Approved Standard M11-A7. CLSI, Wayne, PA, USA, 2007.
27. EUCAST. v. 2.6. 2010. www.eucast.org (30 April 2011, date last accessed).
28. Stubbs SL, Brazier JS, O'Neill GL et al. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999; 37: 461-3.
29. Cohen SH, Tang YJ, Silva J Jr. Analysis of the pathogenicity locus in Clostridium difficile strains. J Infect Dis 2000; 181: 659-63.
30. Sutcliffe J, Grebe T, Tait-Kamradt A et al. Detection of erythromycin-resistant determinants by PCR. Antimicrob Agents Chemother 1996; 40: 2562-6.
31. Spigaglia P, Carattoli A, Barbanti F et al. Detection of gyrA and gyrB mutations in Clostridium difficile isolates by real-time PCR. Mol Cell Probes 2010; 24: 61-7.
32. Taori SK, Hall V, Poxton I. Changes in antibiotic susceptibility and ribotypes in Clostridium difficile isolates from southern Scotland, 1979- 2004. J Med Microbiol 2009; 59: 338-44.
33. Spigaglia P, Barbanti F, Dionisi AM et al. Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018. J Clin Microbiol 2010; 48: 2892-6.
34. Solomon K, Murray S, Scott L et al. An investigation of sub-type diversity of clinical isolates of Irish Clostridium difficile ribotypes 027 and 078 by repetitive-extragenic palindromic PCR. J Med Microbiol 2011; doi:10.1099/jmm.0-029983-0.
35. Sebaihia M, Wren BW, Mullany P et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 2006; 38: 779-86.
36. Stabler RA, He M, Dawson L et al. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol 2009; 10: R102.
37. Piddock LJ. Multidrug-resistance efflux pumps - not just for resistance. Nat Rev 2006; 4: 629-36.
38. Poole K. Efflux pumps as antimicrobial resistance mechanisms. Ann Med 2007; 39: 162-76.
39. Saxton K, Baines SD, Freeman J et al. Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. Antimicrob Agents Chemother 2009; 53: 412-20.